Is IQVIA Holdings, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for IQVIA Holdings, Inc. has moved from very expensive to expensive, indicating a shift towards a less favorable assessment. The company appears overvalued based on its current metrics, with a P/E ratio of 29, a Price to Book Value of 6.50, and an EV to EBITDA of 15.15. In comparison, Laboratory Corp. of America Holdings has a fair P/E of 29.20, while Quest Diagnostics, Inc. shows a fair P/E of 27.82, suggesting that IQVIA is trading at a premium relative to its peers.
In terms of recent performance, IQVIA has outperformed the S&P 500 over the past week and month, with returns of 3.22% and 9.57%, respectively. However, its year-to-date return of 4.09% and one-year return of -12.54% indicate a struggle to keep pace with the broader market, which reinforces the notion that the stock may be overvalued at its current price of 204.55.